<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Progestogen-Only Contraception | Clinical Quick Reference</title>
  <style>
    /* Global Styles */
    * {
      margin: 0;
      padding: 0;
      box-sizing: border-box;
    }

    body {
      font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
      background-color: #f8f9fa;
      color: #333;
      line-height: 1.6;
    }

    .container {
      max-width: 900px;
      margin: 20px auto;
      padding: 20px;
      background: #fff;
      border-radius: 12px;
      box-shadow: 0 6px 18px rgba(0, 0, 0, 0.1);
    }

    header {
      text-align: center;
      margin-bottom: 25px;
      border-bottom: 2px solid #007acc;
      padding-bottom: 15px;
    }

    h1 {
      font-size: 28px;
      color: #005a8c;
      font-weight: 600;
    }

    h2 {
      font-size: 20px;
      color: #007acc;
      margin: 20px 0 10px;
      border-left: 4px solid #007acc;
      padding-left: 10px;
    }

    p {
      margin: 8px 0;
      font-size: 15px;
    }

    /* Table Styling */
    table {
      width: 100%;
      border-collapse: collapse;
      margin: 15px 0;
      font-size: 15px;
    }

    th, td {
      padding: 10px;
      text-align: left;
      border-bottom: 1px solid #ddd;
    }

    th {
      background-color: #007acc;
      color: white;
    }

    tr:nth-child(even) {
      background-color: #f2f8fc;
    }

    /* Lists & Icons */
    ul {
      list-style-type: none;
      padding-left: 10px;
    }

    ul li::before {
      content: "•";
      color: #d9534f;
      font-weight: bold;
      display: inline-block;
      width: 1em;
      margin-left: -1em;
    }

    .adverse-effects li::before {
      color: #f0ad4e;
    }

    .info-box {
      background-color: #e7f3ff;
      border-left: 4px solid #007acc;
      padding: 12px 15px;
      margin: 15px 0;
      border-radius: 0 4px 4px 0;
      font-size: 15px;
    }

    .warning {
      background-color: #f9f0f0;
      border-left: 4px solid #d9534f;
      padding: 12px 15px;
      margin: 15px 0;
      border-radius: 0 4px 4px 0;
      font-size: 15px;
      color: #8a1b1b;
    }

    .footer {
      text-align: center;
      margin-top: 30px;
      font-size: 13px;
      color: #777;
      border-top: 1px solid #eee;
      padding-top: 15px;
    }

    @media (max-width: 768px) {
      .container {
        padding: 15px;
      }
      h1 {
        font-size: 24px;
      }
      h2 {
        font-size: 18px;
      }
      table {
        font-size: 14px;
      }
    }
  </style>
</head>
<body>

  <div class="container">
    <header>
      <h1>Progestogen-Only Contraception</h1>
      <p><strong>Clinical Quick Reference Algorithm</strong><br>
      Based on NICE CKS (Nov 2024) | For Fast Decision-Making in Primary Care</p>
    </header>

    <!-- Eligibility -->
    <h2>1. Patient Eligibility</h2>
    <p><strong>Age:</strong> 13–60 years (female)</p>
    <p><strong>Key Rule:</strong> Use <strong>UKMEC</strong> to assess safety.</p>
    <ul>
      <li>Active breast cancer → <strong>UKMEC 4</strong> (contraindicated)</li>
      <li>Most conditions (e.g., hypertension, migraine) → <strong>UKMEC 1–2</strong> (safe)</li>
    </ul>

    <!-- Methods Overview -->
    <h2>2. Methods Overview</h2>
    <table>
      <thead>
        <tr>
          <th>Method</th>
          <th>Examples</th>
          <th>Duration</th>
          <th>Efficacy</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td><strong>POP (Mini-pill)</strong></td>
          <td>Norethisterone (Noriday®)<br>Desogestrel (Zelleta®)</td>
          <td>Daily</td>
          <td>~99% / 91%</td>
        </tr>
        <tr>
          <td><strong>Implant</strong></td>
          <td>Etonogestrel (Nexplanon®)</td>
          <td>3 years</td>
          <td>>99%</td>
        </tr>
        <tr>
          <td><strong>Injectable</strong></td>
          <td>DMPA (Depo-Provera®)<br>Sayana Press®</td>
          <td>12–13 weeks</td>
          <td>>99%</td>
        </tr>
      </tbody>
    </table>
    <div class="info-box">
      <strong>Note:</strong> Desogestrel POPs (e.g., Zelleta®) have a 12-hour window vs. 3-hour for others.
    </div>

    <!-- Starting -->
    <h2>3. Starting Contraception</h2>
    <p><strong>General Rule:</strong> Start on days 1–5 of cycle → <strong>no backup needed</strong>.</p>
    <ul>
      <li>After day 5? Use condoms/abstinence for <strong>7 days (POP)</strong> or <strong>7–14 days (implant/injectable)</strong>.</li>
      <li><strong>Postpartum (non-breastfeeding):</strong> Start POP/injectable at <strong>day 21</strong>; implant at <strong>day 21–28</strong>.</li>
      <li><strong>Post-abortion/miscarriage:</strong> Start immediately if <24 weeks.</li>
    </ul>

    <!-- Switching -->
    <h2>4. Switching Methods</h2>
    <p><strong>Direct switch</strong> between progestogen-only methods → <strong>no gap, no backup</strong>.</p>
    <p>From combined hormonal contraception → switch on day 1 of pill-free interval or after last active pill.</p>

    <!-- Advantages & Disadvantages -->
    <h2>5. Key Safety & Advice</h2>
    <ul>
      <li><strong>✅ Advantages:</strong> No estrogen (safe in thrombotic risk, migraine), breastfeeding-safe, high adherence (LARC)</li>
      <li><strong>⚠️ Adverse Effects:</strong> Irregular bleeding, weight gain (esp. injectable), BMD ↓ with long-term DMPA</li>
    </ul>

    <!-- Drug Interactions -->
    <h2>6. Drug Interactions</h2>
    <div class="warning">
      <strong>⛔ Enzyme-inducing drugs</strong> (e.g., carbamazepine, rifampicin, St John’s wort):<br>
      Reduce efficacy of POPs/injectables.<br>
      <strong>Implant remains effective (UKMEC 1)</strong>.<br>
      For others: Use alternative (e.g., copper IUD) or backup.
    </div>

    <!-- Managing Issues -->
    <h2>7. Managing Common Issues</h2>
    <ul>
      <li><strong>Unscheduled Bleeding:</strong> Reassure; rule out pregnancy/STIs if persistent.</li>
      <li><strong>Missed POP:</strong>
        <ul style="margin-left: 15px;">
          <li>Desogestrel: >12h late → backup for 7 days</li>
          <li>Other POPs: >3h late → backup for 2 days</li>
        </ul>
      </li>
      <li><strong>Injectable timing:</strong> Repeat every 12 weeks; up to 13 weeks acceptable. >13 weeks? → restart with 7-day backup.</li>
      <li><strong>Pregnancy with implant?</strong> Remove if possible (risk of ectopic).</li>
    </ul>

    <!-- Follow-up -->
    <h2>8. Follow-up & Monitoring</h2>
    <ul>
      <li>Injectables: Monitor weight, BMD with long-term use (>2 years)</li>
      <li>All methods: Annual review for side effects, adherence, risk changes</li>
    </ul>

    <!-- NICE Quality Standard -->
    <h2>9. NICE Quality Standard</h2>
    <div class="info-box">
      <strong>Women must be offered information and choice of all methods, including LARC.</strong>
    </div>

    <div class="footer">
      <p>References: NICE CKS – Contraception (Progestogen-Only), Nov 2024 | FSRH Guidelines</p>
      <p>© Clarity Informatics Ltd (Agilio). Used under licence.</p>
    </div>
  </div>

</body>
</html>